• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

异基因造血干细胞移植后的晚期心血管事件:欧洲血液与骨髓移植组晚期效应工作组的一项回顾性多中心研究

Late cardiovascular events after allogeneic hematopoietic stem cell transplantation: a retrospective multicenter study of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation.

作者信息

Tichelli André, Passweg Jakob, Wójcik Dorota, Rovó Alicia, Harousseau Jean-Luc, Masszi Tamas, Zander Axel, Békássy Albert, Crawley Charles, Arat Mutlu, Sica Simona, Lutz Patrick, Socié Gérard

机构信息

Department of Hematology, University Hospital, CH 4031-Basel, Switzerland.

出版信息

Haematologica. 2008 Aug;93(8):1203-10. doi: 10.3324/haematol.12949. Epub 2008 Jun 12.

DOI:10.3324/haematol.12949
PMID:18556401
Abstract

BACKGROUND

Long-term outcome after hematopoietic stem cell transplantation including late transplant-related events is of increasing interest. The aim of this study was to evaluate the incidence of cardiovascular events after allogeneic HSCT and to search for their risk factors.

DESIGN AND METHODS

This is a retrospective multicenter European Group of Blood and Marrow Transplantation (EBMT) analysis, including 548 long-term survivors treated in ten EBMT transplant centers, who underwent hematopoietic stem cell transplantation between 1990 and 1995 and survived >or=1 year after the transplant. All arterial events occurring after hematopoietic stem cell transplantation (cerebral, coronary, peripheral) were reported.

RESULTS

Twenty (3.6%) out of 548 patients had a cardiovascular event in at least one arterial territory. The median age at occurrence of cardiovascular events was 54 years (range, 41-70). The cumulative incidence of a first arterial event 15 years after hematopoietic stem cell transplantation was 6% (95% CI, 3%-10%). The cumulative incidence for patients with a high global cardiovascular risk score, defined as having >or=50% of the risk factors (arterial hypertension, diabetes, dys-lipidemia, increased body-mass index, physical inactivity, smoking) was 17%, as compared to 4% in those with a low risk score. In multivariate analysis age older than 30 years at last follow-up, and a high global cardiovascular risk score were associated with, respectively, 6.4-fold and 9.8-fold increases in the risk of an arterial event.

CONCLUSIONS

Long-term survivors after allogeneic hematopoietic stem cell transplantation are likely to have an increased risk of premature cardiovascular accidents.

摘要

背景

造血干细胞移植后的长期结局,包括晚期移植相关事件,越来越受到关注。本研究的目的是评估异基因造血干细胞移植后心血管事件的发生率,并寻找其危险因素。

设计与方法

这是一项回顾性多中心欧洲血液与骨髓移植组(EBMT)分析,纳入了在10个EBMT移植中心接受治疗的548例长期存活者,他们于1990年至1995年间接受了造血干细胞移植,且移植后存活≥1年。报告了造血干细胞移植后发生的所有动脉事件(脑、冠状动脉、外周动脉)。

结果

548例患者中有20例(3.6%)至少在一个动脉区域发生了心血管事件。发生心血管事件的中位年龄为54岁(范围41 - 70岁)。造血干细胞移植后15年首次动脉事件的累积发生率为6%(95%CI,3% - 10%)。全球心血管风险评分高的患者(定义为具有≥50%的危险因素,即动脉高血压、糖尿病、血脂异常、体重指数增加、缺乏运动、吸烟)累积发生率为17%,而风险评分低的患者为4%。多因素分析显示,末次随访时年龄大于30岁以及全球心血管风险评分高分别使动脉事件风险增加6.4倍和9.8倍。

结论

异基因造血干细胞移植后的长期存活者发生过早心血管意外的风险可能增加。

相似文献

1
Late cardiovascular events after allogeneic hematopoietic stem cell transplantation: a retrospective multicenter study of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation.异基因造血干细胞移植后的晚期心血管事件:欧洲血液与骨髓移植组晚期效应工作组的一项回顾性多中心研究
Haematologica. 2008 Aug;93(8):1203-10. doi: 10.3324/haematol.12949. Epub 2008 Jun 12.
2
Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study.造血干细胞移植治疗多发性硬化症。一项回顾性多中心研究。
J Neurol. 2002 Aug;249(8):1088-97. doi: 10.1007/s00415-002-0800-7.
3
Hypertension and diabetes mellitus in adult and pediatric survivors of allogeneic hematopoietic cell transplantation.异基因造血细胞移植成年和儿童幸存者中的高血压与糖尿病
Biol Blood Marrow Transplant. 2009 Sep;15(9):1100-7. doi: 10.1016/j.bbmt.2009.05.010.
4
Risk for secondary thyroid carcinoma after hematopoietic stem-cell transplantation: an EBMT Late Effects Working Party Study.造血干细胞移植后发生继发性甲状腺癌的风险:一项欧洲血液与骨髓移植协会迟发效应工作组的研究
J Clin Oncol. 2007 Jun 10;25(17):2449-54. doi: 10.1200/JCO.2006.08.9276.
5
Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).2006年欧洲慢性髓性白血病的异基因造血干细胞移植:移植活性、长期数据及当前结果。欧洲血液与骨髓移植组(EBMT)慢性白血病工作组的一项分析
Haematologica. 2006 Apr;91(4):513-21. Epub 2006 Mar 1.
6
Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO).骨髓纤维化中的异基因造血干细胞移植:意大利骨髓移植协作组(GITMO)的20年经验
Haematologica. 2008 Oct;93(10):1514-22. doi: 10.3324/haematol.12828. Epub 2008 Aug 25.
7
Risk factors for late infections after allogeneic hematopoietic stem cell transplantation from a matched related donor.来自匹配相关供体的异基因造血干细胞移植后晚期感染的危险因素。
Biol Blood Marrow Transplant. 2007 Nov;13(11):1304-12. doi: 10.1016/j.bbmt.2007.07.007. Epub 2007 Sep 7.
8
Chronic kidney disease after myeloablative allogeneic hematopoietic stem cell transplantation.清髓性异基因造血干细胞移植后的慢性肾脏病
Biol Blood Marrow Transplant. 2007 Oct;13(10):1169-75. doi: 10.1016/j.bbmt.2007.06.008. Epub 2007 Jul 27.
9
Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis.异基因造血干细胞移植后结局的风险评分:一项回顾性分析
Cancer. 2009 Oct 15;115(20):4715-26. doi: 10.1002/cncr.24531.
10
Similar risks for chronic kidney disease in long-term survivors of myeloablative and reduced-intensity allogeneic hematopoietic cell transplantation.清髓性和减低强度异基因造血细胞移植长期存活者患慢性肾脏病的风险相似。
Biol Blood Marrow Transplant. 2008 Jun;14(6):658-63. doi: 10.1016/j.bbmt.2008.03.008.

引用本文的文献

1
Dietary Micronutrient Intake in Long-Term Survivors of Pediatric Hematopoietic Stem Cell Transplantation.儿童造血干细胞移植长期存活者的膳食微量营养素摄入量
Nutrients. 2025 May 13;17(10):1663. doi: 10.3390/nu17101663.
2
Multidisciplinary Management of Morbidities Associated with Chronic Graft-Versus-Host Disease.慢性移植物抗宿主病相关并发症的多学科管理
Clin Hematol Int. 2024 Oct 21;6(4):74-88. doi: 10.46989/001c.124926. eCollection 2024.
3
Long-term outcome of 2-year survivors after allogeneic hematopoietic cell transplantation for acute leukemia.
急性白血病异基因造血细胞移植后2年生存者的长期预后
Hemasphere. 2024 Oct 22;8(10):e70026. doi: 10.1002/hem3.70026. eCollection 2024 Oct.
4
Cardiac events occurring after allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide. Study conducted on behalf of the GETH-TC.接受移植后环磷酰胺的异基因造血细胞移植后发生的心脏事件。代表GETH-TC开展的研究。
Bone Marrow Transplant. 2024 Dec;59(12):1694-1703. doi: 10.1038/s41409-024-02414-z. Epub 2024 Sep 14.
5
Cardiovascular Disease After Hematopoietic Stem Cell Transplantation in Adults: State-of-the-Art Review.成人造血干细胞移植后的心血管疾病:最新综述
JACC CardioOncol. 2024 Aug 20;6(4):475-495. doi: 10.1016/j.jaccao.2024.06.004. eCollection 2024 Aug.
6
Cardiac events after allo-HCT in patients with acute myeloid leukemia.异基因造血干细胞移植后急性髓系白血病患者的心脏事件。
Blood Adv. 2024 Nov 12;8(21):5497-5509. doi: 10.1182/bloodadvances.2024013535.
7
Cardiovascular Considerations in Patients Undergoing Hematopoietic Cell Transplantation.造血干细胞移植患者的心血管考虑因素。
Curr Treat Options Oncol. 2024 Aug;25(8):1027-1037. doi: 10.1007/s11864-024-01240-1. Epub 2024 Jul 25.
8
EASIX and cardiac adverse events after allogeneic hematopoietic cell transplantation.异基因造血细胞移植后的EASIX与心脏不良事件
Bone Marrow Transplant. 2024 Jul;59(7):974-982. doi: 10.1038/s41409-024-02270-x. Epub 2024 Mar 23.
9
International recommendations for screening and preventative practices for long-term survivors of transplantation and cellular therapy: a 2023 update.国际移植和细胞治疗长期幸存者的筛查和预防建议:2023 年更新版。
Bone Marrow Transplant. 2024 Jun;59(6):717-741. doi: 10.1038/s41409-023-02190-2. Epub 2024 Feb 27.
10
International Recommendations for Screening and Preventative Practices for Long-Term Survivors of Transplantation and Cellular Therapy: A 2023 Update.国际移植和细胞治疗长期幸存者筛查和预防建议:2023 年更新版。
Transplant Cell Ther. 2024 Apr;30(4):349-385. doi: 10.1016/j.jtct.2023.12.001. Epub 2024 Feb 27.